AstraZeneca CEO Pascal Soriot highlighted that artificial intelligence (AI) is significantly enhancing the company's ability to develop medicines faster and make smarter research decisions. AI tools help identify promising drug targets, optimize molecules to reduce side effects, and improve the chances of success in costly clinical trials. Through partnerships with Tempus AI and Pathos, AstraZeneca uses AI models to analyze clinical and laboratory data, increasing the probability of success in late-stage trials and improving productivity. This advancement could save hundreds of millions of dollars per trial and accelerate innovation across AstraZeneca's drug pipeline.
Rumors about a merger between AstraZeneca PLC and Bristol-Myers Squibb Company have cooled down, but both companies remain strong players in cancer and immune-mediated inflammatory diseases markets. Each company has distinct advantages and some weakn...
Kailera Therapeutics recently closed at $18.51, down 2.5% for the week and 28.8% since its April IPO. The clinical-stage company, with no product revenue, holds $1.17 billion in cash and has a runway into mid-2028. Its lead drug, ribupatide, is in gl...
AstraZeneca retained a 'buy' rating from Citi despite mixed updates on its drug pipeline. Positive Phase III trial results for Tagrisso plus Orpathys in lung cancer showed significant survival benefits, with Citi estimating $500 million in peak sales...
AstraZeneca announced positive late-stage trial results for a two-drug combination treating a resistant form of lung cancer. The combo pairs Tagrisso, an established lung cancer pill, with Orpathys, a newer drug targeting the MET protein that causes ...
